Levocarnitine versus amantadine crossover comparison
L-carnitine
12 of 18 measured clinical parameters improved significantly after eight weeks.
Amantadine
15/30 discontinued, and the authors reported no significant clinical improvement among those who completed treatment.
12 of 18 measured clinical parameters improved significantly after eight weeks.
Study notes · methods, sources and limitations
Participants or model 30 patients with CFS
Design Eight weeks each of oral L-carnitine and amantadine with a two-week washout. The original paper used L-carnitine 1 g three times daily and amantadine 100 mg once daily for one week, then twice daily.
Important limitations
The trial lacked an inactive control. High amantadine discontinuation and multiple measured parameters limit comparisons.
Russian ME/CFS and fatigue research · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
Levocarnitine versus amantadine crossover comparison (1997)
Study methods
30 patients with CFS. Eight weeks each of oral L-carnitine and amantadine with a two-week washout. The original paper used L-carnitine 1 g three times daily and amantadine 100 mg once daily for one week, then twice daily.
Independent replication
The trial lacked an inactive control. High amantadine discontinuation and multiple measured parameters limit comparisons.
Source access
The linked study records provide the original articles or trial registrations.
Safety evidence
Available adverse-event findings and follow-up periods appear in the study notes.
Open a topic for the evidence assessment.
More findings, background and history
What remains unclear
Group assignment, comparators, planned outcomes, effect estimates, adverse events and possible participant overlap are key limits to interpreting the studies.
Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
2016 · RU2578412C1 · Bemitil plus carnitine: asthenia and fatigue claimsFormulation · Combination reportedly reduced fatigue in swim and rotating-rod tests at a selected tested combination
Reported findings
The combination improved some fatigue- and depression-like behaviors, while episodic-memory testing was neutral.
Physical-fatigue tasks
Combination reportedly reduced fatigue in swim and rotating-rod tests at a selected tested combinationExact mean differences not transcribed; individual drugs and combinations differed
Depression-like behavior
Reduced stress-associated immobility reported across tested combination exposuresBehavioral proxy, not clinical depression recovery
2016 · Bemitil plus carnitine: asthenia and fatigue claims — RU2578412C1Physical-fatigue tasks: Combination reportedly reduced fatigue in swim and rotating-rod tests at a selected tested combination
2016Patent / reported experimentsFull text available
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
The combination improved some fatigue- and depression-like behaviors, while episodic-memory testing was neutral.
Results and tables
Reported patent results
Reported findings
The combination improved some fatigue- and depression-like behaviors, while episodic-memory testing was neutral.
Repeated-stress mouse experiments comparing Bemitil, levocarnitine and their combination; not a human ME/CFS trial.
Results · Final repeated-stress experiments and novel-object Table 15 narrative.
Measure
Result
Comparison, timing and statistics
Physical-fatigue tasks
Combination reportedly reduced fatigue in swim and rotating-rod tests at a selected tested combination
Exact mean differences not transcribed; individual drugs and combinations differed
Depression-like behavior
Reduced stress-associated immobility reported across tested combination exposures
Behavioral proxy, not clinical depression recovery
Episodic memory
No detected effect of the tested substances; stress itself did not significantly impair this endpoint
Control preference index 67.7 ± 4.4%; neutral treatment result retained
Animal stress tasks and a combination do not establish Bemitil monotherapy, ME/CFS benefit or synergy. A neutral memory test cannot be rephrased as cognitive improvement.
Repeated-stress mouse experiments comparing Bemitil, levocarnitine and their combination; not a human ME/CFS trial.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
This is a combination, not Etomerzol and not a demonstration of Bemitil monotherapy efficacy in ME/CFS.
Animal stress tasks and a combination do not establish Bemitil monotherapy, ME/CFS benefit or synergy. A neutral memory test cannot be rephrased as cognitive improvement.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Read the source ↗1997 · Levocarnitine versus amantadine crossover comparisonL-carnitine: 12 of 18 measured clinical parameters improved significantly after eight weeks.
12 of 18 measured clinical parameters improved significantly after eight weeks.
Results and tables
Reported findings and study design
Reported findings
Eight weeks each of oral L-carnitine and amantadine with a two-week washout. The original paper used L-carnitine 1 g three times daily and amantadine 100 mg once daily for one week, then twice daily.
Dose, route and schedule
Eight weeks each of oral L-carnitine and amantadine with a two-week washout. The original paper used L-carnitine 1 g three times daily and amantadine 100 mg once daily for one week, then twice daily.
Eight weeks each of oral L-carnitine and amantadine with a two-week washout. The original paper used L-carnitine 1 g three times daily and amantadine 100 mg once daily for one week, then twice daily.
Study limitations
The trial lacked an inactive control. High amantadine discontinuation and multiple measured parameters limit comparisons.